Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma

Abstract Glioblastoma (GBM) is an aggressive and incurable tumor of the brain with limited treatment options. Current first-line standard of care is the DNA alkylating agent temozolomide (TMZ), but this treatment strategy adds only ~4 months to median survival due to the rapid development of resista...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: D. M. Tiek, J. D. Rone, G. T. Graham, E. L. Pannkuk, B. R. Haddad, R. B. Riggins
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d04b39e1ba5c4c6ea68bb0a9360fff81
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares